Literature DB >> 22433754

A review of the cost of atrial fibrillation.

Walter P Wodchis1, R Sacha Bhatia, Kori Leblanc, Nazanin Meshkat, Dante Morra.   

Abstract

OBJECTIVES: To systematically review and synthesize the literature on the costs of atrial fibrillation (AF) with attention to study design and costing methods, geography, and intervention approaches.
METHODS: A systematic search for previously published studies reporting the costs for AF patients was conducted. Data were analyzed in three steps: first by evaluating overall system costs; second by evaluating the relative contribution of specific cost components; and third by examining variations across study designs, across primary treatment approach, and by geography. Finally, a specific review of the treatment costs associated with anticoagulation treatment was examined given the clinical importance and attention given to these costs in the literature.
RESULTS: The literature search resulted in 115 articles. On review of the abstracts or full text of these articles, 21 articles met all study criteria and reported on health system AF-related direct costs. A further six articles focused exclusively on anticoagulation costs for patients with AF. The overall average annual system cost across 27 estimates obtained from the literature was $5450 (SD = $3624) in 2010 Canadian dollars and ranged from a low of $1,632 to a high of $21,099. About one-third of these costs could be attributed to anticoagulation management. The largest cost component was acute care, followed by outpatient and physician and then medication-related costs.
CONCLUSION: AF-related medical costs are high, reflecting resource-intensive and long-term treatments including anticoagulation treatment. These costs, accompanied with increasing prevalence, justify increased attention to the management of patients with AF. Future studies of AF cost should ensure a broad assessment of the incremental direct medical and societal cost associated with this diagnosis. Copyright Â
© 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22433754     DOI: 10.1016/j.jval.2011.09.009

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  21 in total

Review 1.  Population-Based Screening for Atrial Fibrillation.

Authors:  Shaan Khurshid; Jeffrey S Healey; William F McIntyre; Steven A Lubitz
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

2.  Atrial Fibrillation and Heart Failure: How Should We Manage Our Patients?

Authors:  Farhan Shahid; Gregory Y H Lip
Journal:  Arrhythm Electrophysiol Rev       Date:  2016

3.  Costs of Invasive Meningococcal Disease: A Global Systematic Review.

Authors:  Bing Wang; Renee Santoreneos; Hossein Afzali; Lynne Giles; Helen Marshall
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

Review 4.  Primary Prevention of Atrial Fibrillation where are we in 2012?

Authors:  Massimo Imazio
Journal:  J Atr Fibrillation       Date:  2012-08-20

5.  Direct cost for initial management of prostate cancer: a systematic review.

Authors:  C Sanyal; A G Aprikian; S Chevalier; F L Cury; A Dragomir
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

Review 6.  Admission Severity of Atrial-Fibrillation-Related Acute Ischemic Stroke in Patients under Anticoagulation Treatment: A Systematic Review and Meta-Analysis.

Authors:  Catarina Garcia; Marcelo Silva; Mariana Araújo; Mariana Henriques; Marta Margarido; Patrícia Vicente; Hipólito Nzwalo; Ana Macedo
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

7.  Current Evidence and Recommendations for Rate Control in Atrial Fibrillation.

Authors:  Abhishek Maan; Moussa Mansour; Jeremy N Ruskin; E Kevin Heist
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-04

8.  Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-05-28       Impact factor: 3.327

Review 9.  Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Authors:  Kate McKeage
Journal:  Pharmacoeconomics       Date:  2012-09-01       Impact factor: 4.558

10.  Surveillance for Outcomes Selected as Atrial Fibrillation Quality Indicators in Canada: 10-Year Trends in Stroke, Major Bleeding, and Heart Failure.

Authors:  Stephen B Wilton; Padma Kaul; Sunjidatul Islam; Clare L Atzema; Jennifer Cruz; Kendra MacFarlane; Robert McKelvie; Stephanie Poon; Laurie Lambert; Kathy Rush; Marc Deyell; D George Wyse; Jafna L Cox; Allan Skanes; Roopinder K Sandhu
Journal:  CJC Open       Date:  2021-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.